These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15228675)

  • 61. Antisense '97: a roundtable on the state of the industry.
    Nat Biotechnol; 1997 Jun; 15(6):519-24. PubMed ID: 9181572
    [No Abstract]   [Full Text] [Related]  

  • 62. Immunologic consequences of nucleic acid therapy.
    Pisetsky DS
    Antisense Res Dev; 1995; 5(3):219-25. PubMed ID: 8785478
    [No Abstract]   [Full Text] [Related]  

  • 63. Oligonucleotide therapeutics: coming 'round the clubhouse turn.
    Hawkins JW
    Antisense Res Dev; 1995; 5(1):1. PubMed ID: 7613070
    [No Abstract]   [Full Text] [Related]  

  • 64. Marking milestones.
    Steele F
    Nucleic Acid Ther; 2013 Aug; 23(4):243. PubMed ID: 23902359
    [No Abstract]   [Full Text] [Related]  

  • 65. Presentations from the 2nd NIH Symposium on Therapeutic Oligonucleotides: Targeting Transcription Factors and Signaling Pathways. Bethesda, Maryland, USA. December 5, 1997.
    Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):113-84. PubMed ID: 9669868
    [No Abstract]   [Full Text] [Related]  

  • 66. Gene therapy in gastroenterology.
    Pandha HS; Lemoine NR
    Gut; 1996 Feb; 38(2):161-5. PubMed ID: 8801190
    [No Abstract]   [Full Text] [Related]  

  • 67. Slivers of the spectrum.
    Branca M
    Nat Biotechnol; 2021 May; 39(5):540-545. PubMed ID: 33888895
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A new antisense oligonucleotide therapy?
    Bernard NJ
    Nat Rev Rheumatol; 2018 Dec; 14(12):685. PubMed ID: 30425329
    [No Abstract]   [Full Text] [Related]  

  • 69. An antisense oligonucleotide to target the RAAS.
    Fernández-Ruiz I
    Nat Rev Cardiol; 2021 Aug; 18(8):544. PubMed ID: 34040182
    [No Abstract]   [Full Text] [Related]  

  • 70. The Evolution of Antisense Oligonucleotide Chemistry-A Personal Journey.
    Agrawal S
    Biomedicines; 2021 May; 9(5):. PubMed ID: 34063675
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Gene transfer and antisense nucleic acid techniques.
    Miller N; Vile RG
    Parasitol Today; 1994 Mar; 10(3):92-7. PubMed ID: 15275488
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cholesterol-lowering oligonucleotides pass preclinical milestone.
    O'Leary K
    Nat Med; 2021 May; ():. PubMed ID: 34017138
    [No Abstract]   [Full Text] [Related]  

  • 73. Oligonucleotides get triglycerides under control.
    O'Leary K
    Nat Med; 2021 May; ():. PubMed ID: 33963310
    [No Abstract]   [Full Text] [Related]  

  • 74. Developing antisense oligonucleotide and short-interfering RNA therapeutics - a few considerations.
    Cotreau MM
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):323-5. PubMed ID: 27137140
    [No Abstract]   [Full Text] [Related]  

  • 75. RNase H sequence preferences influence antisense oligonucleotide efficiency.
    Kiełpiński ŁJ; Hagedorn PH; Lindow M; Vinther J
    Nucleic Acids Res; 2019 Mar; 47(5):2701. PubMed ID: 30715421
    [No Abstract]   [Full Text] [Related]  

  • 76. Antisense Oligonucleotide Therapy for Spinocerebellar Ataxias: Good News for Terrible Diseases.
    Teive HAG; Camargo CHF; Munhoz RP
    Mov Disord Clin Pract; 2018; 5(4):402-403. PubMed ID: 30838293
    [No Abstract]   [Full Text] [Related]  

  • 77. Correction to: Current Status of Antisense Oligonucleotide-Based Therapy in Neuromuscular Disorders.
    Bizot F; Vulin A; Goyenvalle A
    Drugs; 2020 Sep; 80(14):1417. PubMed ID: 32749652
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Antisense oligonucleotide therapeutics.
    Bennett CF
    Expert Opin Investig Drugs; 1999 Mar; 8(3):237-53. PubMed ID: 15992075
    [No Abstract]   [Full Text] [Related]  

  • 79. Antisense oligonucleotide hope for childhood epilepsies.
    Fyfe I
    Nat Rev Neurol; 2020 Mar; 16(3):128. PubMed ID: 32001838
    [No Abstract]   [Full Text] [Related]  

  • 80. Author Correction: Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease.
    Lidberg KA; Annalora AJ; Jozic M; Elson DJ; Wang L; Bammler TK; Ramm S; Monteiro MB; Himmelfarb J; Marcus CB; Iversen PL; Kelly EJ
    Sci Rep; 2021 May; 11(1):10711. PubMed ID: 34002000
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.